Details of Drug-Drug Interaction
| Drug General Information (ID: DDIVO50AIX) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Procarbazine | Drug Info | Isocarboxazid | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Antidepressants | |||||||
| Structure | |||||||||
| Mechanism of Procarbazine-Isocarboxazid Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive hypertensive effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Procarbazine | Isocarboxazid | |||||||
| Mechanism |
Hypertensive effects Monoamine oxidase non-selective Inhibitor |
Hypertensive effects Monoamine oxidase non-selective Inhibitor |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Monoamine oxidase | Structure Sequence | |||||||
| Protein Family | Flavin monoamine oxidase family | ||||||||
| Protein Function |
Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:20493079, PubMed:8316221, PubMed:18391214, PubMed:24169519). Preferentially oxidizes serotonin (PubMed:20493079, PubMed:24169519). Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity).
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Administration of MAOIs with other MAOIs concurrently or in rapid succession is considered contraindicated. A washout period of at least 7 to 10 days is recommended when switching from one MAOI to another. | ||||||||